AVROBIO Stock Price. Everything You Need To Know About The AVROBIO Stock!
Avrobio, Inc. is a gene therapy company headquartered in Cambridge, Massachusetts, focused on developing innovative lentiviral-based gene therapies to treat rare diseases. Since its IPO on June 21, 2018, the company’s stock price has been closely monitored by investors.
Avrobio’s gene therapies use hematopoietic stem cells that are harvested from the patient and modified with a lentiviral vector to insert a functional copy of the gene that is mutated in the target disease. The company is focused on developing curative ex vivo lentiviral-based gene therapies that provide a single dose treatment regimen to patients with rare genetic diseases.
Avrobio’s pipeline includes five lentiviral-based gene therapy programs that target lysosomal disorders primarily managed with enzyme replacement therapies. These programs include AVR-RD-04 for the treatment of cystinosis, AVR-RD-02 for the treatment of Gaucher disease type 1, AVR-RD-05 for the treatment of Hunter syndrome, AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.
As a leader in the development of gene therapies for rare diseases, Avrobio has the potential to make a significant impact on the healthcare industry. Investors looking for stocks share price today in the biotech sector should consider researching Avrobio and other companies in this field. It’s important to understand the company’s market cap, growth strategy, competitive landscape, and clinical trial progress to make informed investment decisions.
AVROBIO Stock Price. Everything You Need To Know About The AVROBIO Stock! performance
- Employees 78
- Company HQ Cambridge
- Website http://www.avrobio.com
- AVRO Asset Type Common Stock
- AVRO Market Capitalization 54.3M
- Earnings Per Share 0.27
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
AVROBIO is a prominent biotechnology company specializing in developing gene therapies to treat rare diseases. If you are a retail investor from Malaysia, Thailand, Indonesia or Vietnam and looking to invest in AVROBIO, you have come to the right place. At Zorion, our investment platform offers you the opportunity to invest in real US stocks like AVROBIO and Pre-IPO companies, giving you access to potentially high-growth investment options. Our platform also provides investment insights and recommendations to help you make informed decisions about your investment. Additionally, we offer educational resources to enhance your investment knowledge. Start investing in AVROBIO with Zorion today and be a part of the future of gene therapy.
